Please assess the completion status of the following clinical trial:

Trial Title: Point-of-Care Measurements of Platelet Inhibition After Clopidogrel Loading in Patients With Acute Coronary Syndrome: Comparison of Generic Clopidogrel Bisulfate (Plavitor®) With Original Clopidogrel Bisulfate (Plavix®)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with unstable angina or non-ST elevation myocardial infarction~2. Patients who are planned coronary angiography~3. Age \>18 years, \<75 years~4. Patients who agree to the study protocol~Exclusion Criteria:~1. Recent treatment with clopidogrel or pletaal or glycoprotein IIb/IIIa Rc antagonist~2. Active bleeding (peptic ulcer, trauma or intra-cranial hemorrhage)~3. Allergy to antiplatelet agent~4. Bleeding diasthesis (blood coagulation disorders, uncontrolled severe hypertension, history of severe bleeding)~5. History of drug abuse or alcohol abuse~6. ST elevation myocardial infarction~7. Pregnancy~8. Low platelet count (\< 100,000 /L) or abnormal results of PT or PTT~9. Liver disease ( bilirubin \> 2 mg/dL, AST or ALT \> 100 IU)~10. Renal failure ( Cr \> 2.0 mg/dL)~11. Malignancy~12. Proton pump inhibitor, NSAIDs statin (except atorvastatin)

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- original Clopidogrel Bisulfate (Plavix®) (Type: ACTIVE_COMPARATOR): original Clopidogrel Bisulfate (Plavix®) 600mg loading
- generic Clopidogrel Bisulfate (Plavitor®) (Type: EXPERIMENTAL): generic Clopidogrel Bisulfate (Plavitor®) 600mg loading

Based on this trial design, predict the completion outcome and termination type (if applicable).